Study guide

1.2 The Pharmacists' Patient Care Process (PPCP) in Ambulatory Care

Board Certified Ambulatory Care Pharmacist BCACP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Patient Care Process

1.1 BCACP Exam Logistics, Blueprint & Pass Standards 1.2 The Pharmacists' Patient Care Process (PPCP) in Ambulatory Care 1.3 Communication, Health Literacy & Cultural Competence

2 Chapter 2: Cardiovascular I: Hypertension & Dyslipidemia

2.1 Hypertension Guidelines, Staging & Primary Regimens 2.2 Resistant Hypertension, Secondary Causes & Special Populations 2.3 Dyslipidemia: Statin Benefit Groups & Non-Statin Add-ons

3 Chapter 3: Cardiovascular II: Heart Failure, CAD & Anticoagulation

3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management 3.2 Chronic Coronary Disease & Antiplatelet Strategies 3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care

4 Chapter 4: Endocrine & Metabolic Disorders

4.1 Type 2 Diabetes: Incretins, SGLT2i & Comorbidity Alignment 4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia 4.3 Thyroid & Adrenal Disorders in Ambulatory Care 4.4 Osteoporosis Screening, Prevention & Therapeutic Sequencing

5 Chapter 5: Respiratory Care & Pulmonology

5.1 Asthma Management: GINA/NAEPP Stepwise & SMART Therapy 5.2 COPD Management: GOLD Guidelines & Exacerbation Prevention 5.3 Inhalation Devices, Delivery Techniques & Patient Counseling

6 Chapter 6: Renal, Urological & Reproductive Health

6.1 Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care 6.2 Benign Prostatic Hyperplasia & Erectile Dysfunction 6.3 Women's Health: Contraception, Menopause & Teratogenicity

7 Chapter 7: Neuropsychiatry & Behavioral Health

7.1 Major Depressive Disorder & Anxiety Disorders 7.2 Bipolar Disorder & Schizophrenia Spectrum 7.3 Epilepsy & Movement Disorders (Parkinson's Disease) 7.4 Migraine Prevention, Acute Treatment & Headache Disorders

8 Chapter 8: Pain Management & Rheumatology

8.1 Chronic Pain, Opioid Stewardship & SUD Management 8.2 Osteoarthritis, Gout & Hyperuricemia 8.3 Rheumatoid Arthritis & Autoimmune Pharmacotherapy

9 Chapter 9: Infectious Diseases & Immunizations

9.1 Ambulatory Infections & Outpatient Antimicrobial Stewardship 9.2 HIV Pharmacotherapy, PrEP/PEP & Viral Hepatitis 9.3 Adult Immunization Schedules & ACIP Recommendations 9.4 Immunizations in Special & High-Risk Populations

10 Chapter 10: Geriatrics, Drug Interactions & Medication Safety

10.1 Geriatric Pharmacotherapy, Beers Criteria & Deprescribing 10.2 Drug Interactions, CYP450, P-gp & Transporters 10.3 Adverse Drug Events, High-Alert Medications & ISMP Safety

11 Chapter 11: Biostatistics, Study Design & Literature Evaluation

11.1 Biostatistical Principles, Hypothesis Testing & Power 11.2 Clinical Study Designs, Bias & Evidence Appraisal 11.3 Pharmacoeconomics: ICER, QALY & Value Metrics

12 Chapter 12: Practice Advancement, Quality & Healthcare Delivery

12.1 Collaborative Practice Agreements & Telehealth Practice 12.2 Quality Improvement, HEDIS & CMS Star Ratings 12.3 Care Transitions, Medication Reconciliation & SDOH 12.4 CMM Services, CPT Coding (99605-99607) & Practice Management 12.5 Clinical Ethics, Patient Advocacy & Conflicts of Interest

1.2 The Pharmacists' Patient Care Process (PPCP) in Ambulatory Care

Key Takeaways Explain This Topic AI

The Joint Commission of Pharmacy Practitioners (JCPP) PPCP comprises five sequential, cyclical steps: Collect, Assess, Plan, Implement, and Follow-up (Monitor and Evaluate), centered on patient-centered collaboration, communication, and documentation.

Comprehensive Medication Management (CMM) is the direct clinical practice standard ensuring every medication is evaluated for indication (appropriateness), effectiveness, safety, and patient adherence.

Drug Therapy Problems (DTPs) are classified into four overarching clinical categories (Indication, Effectiveness, Safety, Adherence) and seven discrete etiologies under the validated Cipolle/Morley/Strand framework.

Medication Reconciliation (MedRec) technical verification must not be confused with CMM; MedRec identifies discrepancies across transitions of care, whereas CMM provides comprehensive clinical evaluation and longitudinal therapeutic accountability.

DTP prioritization in complex multimorbid ambulatory patients requires triaging immediate life-threatening safety risks and symptomatic adverse reactions before addressing untreated preventative indications.

Last updated: September 2026

The Pharmacists' Patient Care Process (PPCP) in Ambulatory Care

Executive Summary: The Pharmacists' Patient Care Process (PPCP), adopted by the Joint Commission of Pharmacy Practitioners (JCPP), provides a standardized, evidence-based, patient-centered framework applicable across all ambulatory pharmacy settings. Embedded within the Patient-Centered Medical Home (PCMH) and Accountable Care Organization (ACO) care delivery models, the PPCP drives Comprehensive Medication Management (CMM) —ensuring that every single medication (prescription, OTC, herbal, dietary supplement) is evaluated for appropriateness (indication), effectiveness, safety, and patient adherence .

1. The Five Sequential Steps of the PPCP

The PPCP is an iterative, continuous cycle. At the core of the framework sit four foundational pillars: Patient-Centered Care , Collaborate , Communicate , and Document .

Loading diagram... JCPP Pharmacists' Patient Care Process (PPCP) Operational Cycle

Step 1: Collect

The ambulatory care pharmacist systematically gathers relevant subjective and objective clinical information to understand the patient's full medical, medication, and socioeconomic history:

Subjective Data: Patient-reported symptoms, functional lifestyle factors, health beliefs, cultural considerations, economic barriers, dietary patterns, physical activity, and actual medication administration routines (including non-prescription OTCs, herbal products, and vitamins).

Objective Data: Electronic Health Record (EHR) documentation, vital signs (clinic and home blood pressure logs), diagnostic tests (ECGs, echocardiograms, spirometry, DXA scans), laboratory values (serum creatinine, eGFR, electrolytes, HbA1c, lipid profiles, liver function panels), and pharmacy dispensing/fill histories.

Step 2: Assess

The pharmacist analyzes collected clinical data, synthesizing the clinical effects of medication therapy in the context of the patient's overall health goals. Crucially, the pharmacist evaluates:

Each Medication's Clinical Appropriateness: Is there an active, guideline-indicated medical diagnosis for each medication? Are there untreated conditions requiring new therapy?

Effectiveness: Is the current therapy achieving target clinical and surrogate endpoints (e.g., HbA1c <7%, BP <130/80 mmHg, LDL-C reduction ≥50%)?

Safety: Are there adverse drug events, laboratory toxicities, drug-drug/drug-disease interactions, or supratherapeutic dosages?

Adherence: Is the patient taking the medication as prescribed? Are there financial, physical, cognitive, or health literacy barriers?

Preventive Care: Immunization status, cancer screenings, bone mineral density screenings, and lifestyle modifications.

Step 3: Plan

In collaborative partnership with the patient, caregiver, and interprofessional healthcare team (physicians, nurse practitioners, physician assistants, social workers), the pharmacist formulates an individualized, evidence-based, cost-effective care plan:

Addresses all identified Drug Therapy Problems (DTPs) in prioritized order.

Establishes SMART Goals (Specific, Measurable, Achievable, Relevant, Time-bound) for each chronic condition.

Selects optimal pharmacological and non-pharmacological interventions aligned with national guidelines and formulary access.

Details a structured schedule for follow-up, laboratory monitoring, and symptom reassessment.

Step 4: Implement

The pharmacist executes the agreed-upon care plan in collaboration with the healthcare team and the patient:

Initiates, adjusts, titrates, or discontinues medication regimens pursuant to Collaborative Practice Agreements (CPAs) or provider orders.

Orders relevant laboratory monitoring tests (e.g., basic metabolic panel 2 weeks post-ACE inhibitor initiation).

Delivers individualized patient education, self-management training (e.g., insulin injection technique, inhaler device use, home blood glucose monitoring), and adherence coaching.

Makes interprofessional referrals (e.g., Diabetes Self-Management Education [DSME], registered dietitians, ophthalmology, podiatry, medical social work).

Step 5: Follow-Up: Monitor and Evaluate

The pharmacist longitudinally tracks and evaluates the effectiveness and safety of the implemented plan:

Re-evaluates clinical endpoints (lab values, vitals, symptom severity scores).

Reassesses patient medication adherence, tolerability, and emergence of adverse reactions.

Adjusts therapy iteratively until clinical goals are met and maintained.

Standardizes clinical documentation using structured EHR formats (e.g., SOAP note: Subjective, Objective, Assessment, Plan).

2. Comprehensive Medication Management (CMM) vs. MedRec vs. MTM

Board certification requires precise delineation between three distinct medication review paradigms commonly encountered in ambulatory care: ┌─────────────────────────────────────────────────────────────────────────┐

  • │ MEDICATION RECONCILIATION (MedRec) │
  • │ • Technical verification across care transitions (Admission/Discharge) │
  • │ • Goal: Create accurate list; eliminate omissions & duplications │
  • └────────────────────────────────────┬────────────────────────────────────┘
  • ▼
  • ┌─────────────────────────────────────────────────────────────────────────┐
  • │ MEDICATION THERAPY MANAGEMENT (MTM / CMR) │
  • │ • Policy-driven / CMS Medicare Part D service targeting high costs │
  • │ • Goal: Identify gross non-adherence & medication gaps (often remote) │
  • └────────────────────────────────────┬────────────────────────────────────┘
  • ▼
  • ┌─────────────────────────────────────────────────────────────────────────┐
  • │ COMPREHENSIVE MEDICATION MANAGEMENT (CMM) │
  • │ • High-level clinical standard embedded within primary/specialty care │
  • │ • Pharmacist holds clinical accountability under CPA protocols │
  • │ • Goal: Systematic clinical assessment of Indication, Effectiveness, │
  • │ Safety & Adherence for ALL medications to achieve clinical targets │
  • └─────────────────────────────────────────────────────────────────────────┘
  • Detailed Comparison Matrix

Attribute Medication Reconciliation (MedRec) Medication Therapy Management (MTM / CMR) Comprehensive Medication Management (CMM)

Primary Definition The process of creating the most accurate list possible of all medications a patient is taking across care transitions. A distinct service or group of services that optimize therapeutic outcomes for individual patients (often Part D mandated). A standardized clinical practice where the clinical pharmacist assumes accountability for optimizing all medications to achieve specific clinical targets.

Core Purpose To prevent medication errors of omission, duplication, dosing errors, and drug interactions during transitions of care. To educate patients, identify adherence barriers, resolve gap-in-care measures, and reduce total medication spend. To systematically evaluate each medication for indication, effectiveness, safety, and adherence in direct collaboration with physicians.

Practice Setting Inpatient admission/discharge, emergency department, ambulatory clinic check-in. Community pharmacy, health plan call centers, telephonic vendor platforms. Integrated primary care clinics, Patient-Centered Medical Homes (PCMH), specialty clinics (Cardiology, Endocrinology, Nephrology).

Clinical Authority Informational; does not alter prescriptions without prescriber contact. Consultative; provides recommendations to prescribers via fax/EHR. Direct prescriptive authority under Collaborative Practice Agreements (CPAs) or standing medical protocols.

Accountability Responsible for list accuracy at a single point in time. Responsible for completing annual review and documenting recommendations. Longitudinal clinical accountability for achieving disease state clinical endpoints (e.g., HbA1c, BP, lipids).

3. Systematic Identification & Classification of Drug Therapy Problems (DTPs)

A Drug Therapy Problem (DTP) is any undesirable event experienced by a patient that involves, or is suspected to involve, drug therapy, and that interferes with achieving the desired goals of therapy. Under the validated Cipolle, Morley, and Strand framework , DTPs are categorized into 4 Core Categories and 7 Distinct Etiologies .

The 4 Categories and 7 Specific Drug Therapy Problems:

Category 1: Indication

Unnecessary Drug Therapy: The patient is taking a medication without a valid medical indication; multiple drug products are being used for a condition that requires single-drug therapy (duplicate therapy); or medication is being prescribed to treat an avoidable adverse reaction caused by another medication (prescribing cascade).

Clinical Example: A patient continues taking pantoprazole 40 mg daily prescribed during an acute hospitalization 2 years ago for stress ulcer prophylaxis without history of GERD or peptic ulcer disease.

Needs Additional Drug Therapy: A medical condition requires new or added pharmacotherapy (untreated condition, synergistic therapy, or prophylactic/preventive therapy indicated by guidelines).

Clinical Example: A 56-year-old patient with Type 2 Diabetes and established ASCVD is not prescribed a high-intensity statin or an SGLT2 inhibitor/GLP-1 receptor agonist.

Category 2: Effectiveness

Ineffective Drug Product (Wrong Drug): The medication is not the most effective agent for the medical indication; the drug product is not guideline-directed; or the dosage form is inappropriate.

Clinical Example: Prescribing glipizide monotherapy for a patient with symptomatic heart failure with reduced ejection fraction (HFrEF) and uncontrolled diabetes, where an SGLT2 inhibitor provides proven cardiovascular and renal mortality reduction.

Dosage Too Low: The medication dose is too low to produce the desired clinical outcome, the dosing frequency is too long, the duration is too short, or a drug interaction decreases bioavailability/exposure.

Clinical Example: Initiating allopurinol at 100 mg daily for chronic tophaceous gout but failing to titrate the dose upward to achieve the target serum uric acid level <6.0 mg/dL (or <5.0 mg/dL in severe tophaceous disease).

Category 3: Safety

Adverse Drug Reaction (ADR): The drug causes an undesirable allergic, immunologic, or idiosyncratic reaction, or a pharmacologic side effect.

Clinical Example: A patient prescribed lisinopril develops persistent, dry, hacking cough secondary to bradykinin accumulation.

Dosage Too High: The drug dosage is supratherapeutic, the dosing interval is too frequent, or accumulation occurs due to renal/hepatic impairment, leading to toxic drug levels.

Clinical Example: A patient with Stage 4 CKD (eGFR 22 mL/min) receives gabapentin 600 mg three times daily (standard renal dose should not exceed 200–300 mg daily), resulting in severe sedation, dizziness, and ataxia.

Category 4: Adherence

Inappropriate Adherence (Non-Adherence): The patient does not take the medication appropriately due to financial cost, lack of understanding, complex regimen schedule, difficulty swallowing/administering, or personal health beliefs.

Clinical Example: A patient prescribed a brand-name GLP-1 RA omits doses because of a $350 monthly copay.

4. DTP Classification Matrix & Clinical Prioritization Hierarchy

Category DTP Specific Etiology Common Ambulatory Root Causes Clinical Intervention Strategy

Indication 1. Unnecessary Drug Therapy Prescribing cascade, resolved condition, duplicate drug classes Discontinue (deprescribe) unneeded drug; taper if necessary

Indication 2. Needs Additional Therapy Untreated comorbidity, omission of guideline-directed therapy (GDMT), lack of primary/secondary prophylaxis Initiate indicated guideline therapy; order baseline monitoring labs

Effectiveness 3. Ineffective Drug / Wrong Drug Guideline discordance, pharmacogenomic mismatch, inappropriate dosage form Switch to first-line guideline-concordant therapy

Effectiveness 4. Dosage Too Low Failure to titrate to target, drug interaction lowering drug levels, inadequate frequency Titrate dose upward toward target goal; shorten dosing interval

Safety 5. Adverse Drug Reaction Allergic response, known drug side effect, drug interaction producing toxicity Discontinue offending agent; switch to alternative therapeutic class

Safety 6. Dosage Too High Failure to renally adjust, excessive dose, drug interaction elevating drug levels Reduce dose; extend dosing interval; monitor drug levels/toxicity

Adherence 7. Non-Adherence High copay, complex multi-dose regimen, health literacy deficits, side effect anxiety Simplify regimen, switch to generic/PAP assistance, motivational counseling

DTP Clinical Prioritization Hierarchy

When managing complex ambulatory patients with multiple simultaneous DTPs, the pharmacist must establish a clear clinical triage hierarchy: ┌─────────────────────────────────────────────────────────────────────────┐

  • │ PRIORITY 1: ACUTE SAFETY THREATS & SEVERE TOXICITIES │
  • │ • Severe hypoglycemia, acute hyperkalemia, profound bradycardia, │
  • │ toxic drug accumulation in renal failure, anaphylaxis / DRESS. │
  • ├─────────────────────────────────────────────────────────────────────────┤
  • │ PRIORITY 2: SYMPTOMATIC ADVERSE DRUG REACTIONS │
  • │ • Debilitating ACEi cough, statin myalgias causing cessation, severe │
  • │ orthostatic hypotension, opioid-induced constipation. │
  • ├─────────────────────────────────────────────────────────────────────────┤
  • │ PRIORITY 3: INEFFECTIVE THERAPY FOR UNCONTROLLED ACTIVE CONDITIONS │
  • │ • Uncontrolled Stage 2 hypertension (BP >160/100), uncontrolled diabetes│
  • │ with microvascular symptoms, subtherapeutic anticoagulation (INR <2.0)│
  • ├─────────────────────────────────────────────────────────────────────────┤
  • │ PRIORITY 4: UNTREATED PREVENTIVE / SECONDARY PROPHYLAXIS INDICATIONS │
  • │ • Adding statin for primary ASCVD prevention, initiating osteoporosis │
  • │ bisphosphonate, administering pneumococcal/zoster vaccines. │
  • ├─────────────────────────────────────────────────────────────────────────┤
  • │ PRIORITY 5: LONG-TERM OPTIMIZATION & DEPRESCRIBING │
  • │ • Discontinuing unnecessary PPIs, deprescribing Beers criteria meds, │
  • │ switching to 90-day supply / mail order for cost savings. │
  • └─────────────────────────────────────────────────────────────────────────┘